Australian Study Partner - Who is it?, page-3

Good chat here fellas.

Thought I’d throw something else in the mix for EIQ.Been reading about EchoSolv. They ran a trial down at St Vincent’s in Australia and reckon it picked up 72% more cases of severe aortic stenosis than doctors alone. Also fixed up the problem where women weren’t getting diagnosed as often as blokes.

That trial was paid for by Edwards Lifesciences, so there’s some serious backing there.

You can read about it here:https://www.echoiq.ai/wp-content/uploads/2023/08/St-Vincents-Full-Press-Kit-ESC-2023.pdf

Now here’s where it gets interesting. Edwards just put out some new info showing that getting in early and treating AS before folks even get symptoms saves a stack of money and stops people dying. They reckon if you wait till symptoms show up, you’ve got a seven-times higher chance of carking it in a year.

https://ir.edwards.com/news/news-details/2025/Prompt-Intervention-for-Severe-Aortic-Stenosis-Patients-Demonstrates-Lower-Healthcare-Costs-Improved-Clinical-Outcomes/default.aspx

There’s a lot more material on the EIQ website too:

https://www.echoiq.ai/research/

I just downloaded everything and put it into ChatGPT and it gave me this:

“What’s happening here is EchoSolv’s AI is picking up cases that might look moderate on paper but actually behave more like severe AS when you look at how the heart’s working and how sick people end up.

Some research shows that even moderate aortic stenosis can carry nearly the same risk of death as severe, especially when the heart’s pumping isn’t normal. For example:In a big study published in JACC in 2019, researchers found five-year mortality was about 56% in moderate AS, compared to 67% in severe AS. That’s only about an 11% difference—which means people with moderate AS are dying at almost the same rate as those with severe AS, which is a lot higher risk than most folks realise.

Another paper in PLOS ONE in 2022 showed people with moderate AS had a hazard ratio for death around 1.5 to 1.7, not far off the risk seen in severe AS.

And a more recent 2024 meta-analysis in JAHA found 15-year survival dropped to 23% for moderate AS patients, which again is pretty close to severe cases.All of this suggests moderate AS might not be as “mild” as folks once thought.

That’s why Edwards is so interested in catching patients earlier, because treating them sooner could save lives and a lot of hospital costs.

So even though EchoSolv was tested in severe AS, the same tech could be pretty handy spotting those moderate patients who might really need earlier intervention.

Those papers may have helped pave the way for Edwards’ PROGRESS trial, which is looking at whether treating moderate AS earlier with TAVR could improve outcomes.

It’s all pointing in the same direction — finding the right patients sooner rather than waiting until things get worse.”

To me, this all lines up. You’d think this tech could help find people earlier, maybe even folks sitting in that moderate AS bucket before it gets ugly. Edwards is all about catching this stuff earlier. Makes sense they’d be looking at tools like EchoSolv.Anyway, all public info. Just reckon it’s worth keeping on the radar for EIQ, especially if Edwards keeps pushing into treating people sooner rather than later.